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Background: A Drug Influence Evaluation (DIE) is a formal assessment of an impaired driving suspect, performed
by a trained law enforcement officer who uses circumstantial facts, questioning, searching, and a physical exam to
form an unstandardized opinion as to whether a suspect’s driving was impaired by drugs. This paper first identifies
the scientific studies commonly cited in American criminal trials as evidence of DIE accuracy, and second, uses the
QUADAS tool to investigate whether the methodologies used by these studies allow them to correctly quantify the
diagnostic accuracy of the DIEs currently administered by US law enforcement.
Results: Three studies were selected for analysis. For each study, the QUADAS tool identified biases that distorted
reported accuracies. The studies were subject to spectrum bias, selection bias, misclassification bias, verification bias,
differential verification bias, incorporation bias, and review bias. The studies quantified DIE performance with
prevalence-dependent accuracy statistics that are internally but not externally valid.
Conclusion: The accuracies reported by these studies do not quantify the accuracy of the DIE process now used
by US law enforcement. These studies do not validate current DIE practice.
Keywords: MESH terms, Automobile driver examination, Research design, Sensitivity and specificity, Non-MESH,
Drug influence evaluation, Drug recognition expert, Drug evaluation and classification program, Sobriety testingBackground
Law enforcement drug assessment
A Drug Influence Evaluation (DIE) is a formal assess-
ment of an impaired driving suspect, performed by a law
enforcement officer called a Drug Recognition Expert
(DRE). The assessment culminates with the officer’s opin-
ion that the person is, or is not, impaired by a drug be-
longing to one of several categories, or multiple drugs
belonging to multiple categories. In criminal trials DRE of-
ficers’ opinions are used, with or without blood or urine
drug toxicology testing, as evidence of drug impaired driv-
ing. When an officer’s drug category prediction matches
later toxicology results, the correctness of the drug cat-
egory prediction is said to confirm the officer’s opinion
that the suspect was impaired by that drug, according to
the theory outlined in Figure 1. Current US law enforce-
ment DIE practice is overseen by the InternationalCorrespondence: GregKaneMD@hotmail.com
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reproduction in any medium, provided the orAssociation of Chiefs of Police (IACP), which coordinates
the International Drug Evaluation and Classification Pro-
gram, with support from the National Highway Traffic
Safety Administration (NHTSA).
In current forensic practice “Drug Influence Evaluation”
usually refers to the combination of the DRE officer’s as-
sessment of the suspect and toxicology testing. This differs
from the foundational research, which calculated the ac-
curacy with which officers’ opinions matched toxicology
results, and which therefore needed technical terminology
for the suspect assessment and officer’s opinion exclusive
of the toxicology. Different studies used various infelicitous
terms. This paper will refer to the Law Enforcement Drug
Assessment (LEDA) as consisting of two parts 1) the Sus-
pect Assessment (SA), in which data is gathered, and 2)
the officer’s DRE Opinion as to whether or not the sus-
pect’s driving was impaired by drugs. Toxicology testing
may follow, but is not part of a LEDA as the term is used
here. The DIE validation studies investigated in this paperis is an open access article distributed under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 US law enforcement Drug Influence Evaluation theory. 1 Driver fails a Standardized Field Sobriety Test (SFST). 2 A failed SFST always
proves impairment. 3 Breath alcohol test finds a low alcohol level, ruling out alcohol as the cause of impairment proven by SFST. 4 Medical
evaluation by the DRE officer rules out a medical cause of impairment proven by the SFST. 5 DRE exam involving circumstantial facts,
questioning, a physical search (if done), and a physical exam, is used to identify the presence in the subject’s body of a drug belonging to one of
several categories. 6 A trained Drug Recognition Expert opines that the driver is, or is not, impaired by a drug belonging to a particular category.
7 Blood or urine is tested for drugs. 8 Toxicology revealing a drug in the predicted category circles back to confirm the SFST’s proof of
impairment. The person must have been impaired—How else could the officer have made this very specific drug category prediction? Alternatively,
when a drug in the predicted category is not found, some validation study accuracy calculations consider any drug in any other category as
proving impairment—After all the officer predicted a drug, and a drug was found.
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Opinions that correctly predicted toxicology results.
The idea of a formal LEDA was developed by Los
Angeles police officers in the 1970s, and used in local crim-
inal prosecutions without published diagnostic accuracy re-
search. In the early 1980s the National Highway Traffic
Safety Administration (NHTSA) adapted the Los Angeles
program for national use [1]. NHTSA directly sponsored
two police drug recognition validation projects, identified
here as Bigelow [2] and Compton [3], and through the
Arizona Department of Transportation funded a third, Ad-
ler [4]. These three police drug recognition validation pro-
jects were printed by NHTSA (Bigelow, Compton) and the
Arizona Department of Transportation (Adler). Peer re-
viewed studies of LEDA-like testing have also been reported
[5,6] including papers investigating refined interpretation
techniques [7-9] or focused on specific drugs [10-15].Accuracy of diagnostic tests
In general, studies of diagnostic test accuracy reveal a
number of accuracy statistics, including the accuracy of
the test when its answer is Yes (positive predictive value,
PPV), when the answer is correct (overall accuracy), when
administered to people with the target condition (sensitiv-
ity), and when administered to people without the condi-
tion (specificity). These accuracy numbers are generally all
different from each other [16].
The purpose of a DIE is not simply to identify drug
impairment; to be useful the DIE process must tell the
difference between people who are drug impaired and
people who are sober. The accuracy with which a diagnos-
tic test identifies that difference is generally expressed with
the paired statistics sensitivity and specificity [17-21], or
with likelihood ratio [22-24], or the area under the ROC
curve [25,26].
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valid (generalizable to populations other than the one in
the study), some are not. PPV—“arrest accuracy”, or “ac-
curacy of the arresting officers’ toxicology predictions”—
is not externally valid. It depends on prevalence [27-30].
Because the prevalence of drug impairment changes
as time and location change, even when officers make
exactly the same measurements and interpret them with
exactly the same criteria, the accuracy of the officers’
predictions changes depending on where and when the
test is administered.
Diagnostic research methodology
Research to discover the accuracy of a diagnostic test
is conceptually easy: administer the test to a group of
people and see if it works. The test being tested is the
“index test”. Results of the index test are compared with
results of a gold standard “reference test”. The research
question is, “How accurately do index test results predict
the (true, gold standard) reference test results?”
Research to discover the accuracy of diagnostic tests is in
practice very challenging. Devils lurk in the details. What
would seem to be small variations in research methodology
lead to large systematic errors—biases—in a test’s apparent
accuracy [31-33]. Bias affects the validity of a study’s find-
ings [34-36]. It is important not to take reported diagnostic
test accuracies at face value, but instead to evaluate the
underlying research for methodologies known to cause bias
[37-39]. Various authors and groups, particularly those in-
terested in meta-analyses, have suggested checklists and
scoring methods to do this in a systematic way [40-43]. De-
tails differ, the methodologies targeted overlap.
The Quality Assessment of Diagnostic Accuracy Stud-
ies (QUADAS) tool is a set of fourteen questions that in-
vestigate the methodologic quality of scientific studies
that quantify diagnostic test performance [40]. The ques-
tions identify research methodologies known to bias the
accuracies research discovers. QUADAS identifies indi-
vidual methodologic shortcomings, it does not provide a
meaningful composite quality score [44]. Empirical evi-
dence shows that methodologic shortcomings may cause
studies to overestimate the accuracy of diagnostic tests
[45]. When reviewers use the tool, their judgments
about methodologic quality show high rates of agree-
ment [46-48]. QUADAS use is increasing [49].
This paper uses the QUADAS tool to investigate the
methodological quality of the scientific research com-
monly offered in American courts as evidence of the valid-
ity and reliability of the US law enforcement DIE process.
Results and discussion
Study selection
The IACP’s The International Standards of the Drug Evalu-
ation and Classification Program [50], hereafter Standardsidentifies DRE training as having been “validated through
both laboratory and field studies conducted by Johns
Hopkins University”. This cannot be correct. The Johns
Hopkins DRE lab study was Bigelow; there was no
Johns Hopkins DRE field study. At the IACP, the Execu-
tive director did not respond. The two IACP TAP offi-
cials did respond. Neither identified any DIE testing
standards. The TAP’s medical expert did give assurances
that the DIE process includes “guidelines” with a scientific
basis, but he did not name specific validating research.
Pressed for specifics, both TAP officials quit answering
emails or certified mail. The DECP.org web site states that
“NHTSA, and various other agencies and research groups
examined the DEC program. These various studies demon-
strated that a properly trained DRE can successfully identify
drug impairment”. [www.decp.org/about, retrieved March
4, 2013] but the studies themselves are not named. The
DRE Student Manual identifies the accuracy of current DIE
practice as being demonstrated by Bigelow, Compton and
Adler. The NCDD legal expert identified two studies—
Bigelow and Compton—as the those frequently cited in
American criminal trials as evidence of DIE accuracy, and a
third study—Adler—as being important because it is identi-
fied as evidence of the accuracy of DIEs in the official DRE
Student Manual. He identified no other studies as pertinent
to this paper’s defining question. The studies selected for
analysis were Bigelow, Compton and Adler.
Reported accuracies
Bigelow, Compton and Adler each reported a number of
diagnostic accuracy related statistics, some of which were
highlighted:
Bigelow: “Of subjects judged to be intoxicated the cor-
rect drug class was identified on 91.7% of occasions. Over-
all, in 98.7% of instances of judged intoxication the subject
had received some active drug” [Bigelow, page 16].
Compton: “When the DREs claimed drugs other than
alcohol were present they were almost always detected
in the blood (94% of the time)” [Compton, page 22].
Adler: “DRE decisions were supported by laboratory
analysis for 404 (83.5%) of the 484 specimens” [Adler,
page 33].
QUADAS Items
The studies’ research methodologies are summarized in
Appendix 1. QUADAS questions and answers are reported
in Table 1. The QUADAS tool identified research method-
ologies expected to cause bias and to make the accuracies
the studies reported not internally or externally valid. These
are discussed below and summarized in Appendix 2.
QUADAS Item 1—spectrum bias, forensic spectrum bias
It is generally easier to diagnose severe disease than mild
disease. Studies with sample populations skewed toward
Table 1 QUADAS results
Bigelow Compton Adler
1. Was the spectrum of patients representative of the patients who will receive the test in practice? No No No
2. Were selection criteria clearly described? No No No
3. Is the reference standard likely to correctly classify the target condition? No No No
4. Is the time period between reference standard and index test short enough to be reasonably
sure that the target condition did not change between the two tests?
Yes Yes Yes
5. Did the whole sample or a random selection of the sample, receive verification using a reference
standard of diagnosis?
Yes No No
6. Did patients receive the same reference standard regardless of the index test result? Yes No No
7. Was the reference standard independent of the index test (i.e. the index test did not form part
of the reference standard)?
No No No
8. Was the execution of the index test described in sufficient detail to permit replication of the test? No No No
9. Was the execution of the reference standard described in sufficient detail to permit its replication? Yes No No
10. Were the index test results interpreted without knowledge of the results of the reference standard? No No No
11. Were the reference standard results interpreted without knowledge of the results of the index test? Yes No No
12. Were the same clinical data available when test results were interpreted as would be available
when the test is used in practice?
n/a n/a n/a
13. Were uninterpretable/ intermediate test results reported? No No No
14. Were withdrawals from the study explained? No No No
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reflect the accuracy of the identical test in other settings.
When a study selects subjects in a way that distorts the
spectrum of disease severity, a systematic error arises
called spectrum bias.
Bigelow’s lab study confirmed that LEDA accuracy is
subject to spectrum bias. When subjects were given the
same drugs at different doses, DRE Opinions were less
accurate at spotting people given the lower dose than
they were at spotting people given the higher dose. This
effect was found for every drug tested this way. Bigelow
highlighted LEDA accuracies derived from subjects dosed
at high doses, three and six times the usual prescription
level. Bigelow’s accuracies were subject to spectrum bias.
Compton and Adler’s study groups were distorted by
the inclusion only of people arrested for chemically im-
paired driving. These studies were both subject to what
may be called forensic spectrum bias—spectrum bias aris-
ing in sample populations preselected to be guilty beyond
a reasonable doubt.
Compton’s study sample was made up of people who
had already been identified as chemically impaired and
arrested by non-DRE officers. Drivers were then screened
again and included in the study only if their impairment
was apparent on a “cursory exam” [Compton, page 34].
Seventy-two percent of Compton’s subjects had multiple
drugs on board. The accuracies Compton reported were
the accuracies of the LEDA applied to people whose im-
pairment was so obvious it was already apparent to
non-DRE experts and judged to be provable beyond a
reasonable doubt before the LEDA SA physical examwas done. Compton’s accuracies were subject to forensic
spectrum bias.
Adler likewise reports the accuracy of the LEDA on
people who were arrested—people against whom experi-
enced officers concluded a beyond-a-reasonable-doubt legal
case could be made. Most had multiple drugs on board.
Adler’s accuracies were subject to forensic spectrum bias.
QUADAS Item 2—selection bias
When research selects subjects in a way that distorts
test-result-relevant characteristics of the sample of people
in the study compared to the population of people to
whom the test will be administered later, a systematic
error arises called selection bias.
Bigelow’s study group was distorted by the selection
only of healthy young men prescreened to pass the SFST
and then further trained to do the SFST. These subjects
will have been more likely to pass the SFST than would
the older, the unhealthy, the uncoordinated people, and
the people not screened to pass the SFST who are part
of the population the SFST/ LEDA is applied to in police
practice outside the lab. The accuracy of the SFST ad-
ministered to Bigelow’s sample will be different from the
accuracy of the SFST (and thus the LEDA) administered
to the population in general. Bigelow’s accuracies were
subject to selection bias.
Compton and Adler’s study groups were distorted by the
fact that neither study enrolled a series of consecutive
drivers stopped by police. Some drivers were stopped,
assessed and not given a LEDA; they were excluded from
the studies’ accuracy calculations. Other drivers were
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studies’ reported accuracies depend on the performance of
just this group. The accuracies Compton and Adler dis-
covered will have depended on how officers made these
administer/ don’t administer decisions—on how they se-
lected subjects. These selection decisions will have been
made in accordance with local police policies, local prose-
cutors’ policies, local demographics, local drug use pat-
terns, and each officers’ unstandardized personal practices.
The accuracies reported by Compton and Adler were sub-
ject to selection bias.
QUADAS Item 3—misclassification bias
Studies of diagnostic test accuracy quantify the ability of an
index test to predict the results of a reference test. The ref-
erence test is assumed to be a gold standard that correctly
identifies the target condition with 100% accuracy. If the
reference test fails to diagnose the target condition cor-
rectly, a systematic error arises called misclassification bias.
In drugged driving prosecutions the LEDA’s target
condition is the subject’s driving, but none of the three
studies used driving performance or physical or mental
impairment as their reference test. Bigelow’s reference
test was the fact a subject was given a medicine. Comp-
ton and Adler’s reference test was blood or urine testing
for drugs. In each study the reference test and the target
condition were different.
The question raised by QUADAS Item 3 is, “Does
drug in the blood or urine correctly classify people as
drug impaired?” The answer is, it may not. Low levels of
drugs and metabolites are found in the body hours or
even, depending on the drug, days after impairing effects
have ended. The studies themselves recognized they were
subject to misclassification bias. Compton noted,
“There is no way to determine objectively whether the
suspects were actually too ‘impaired’ to drive safely. The
fact that drugs were found in a suspect’s blood does not
necessarily mean the suspect was too impaired to drive
safely” [Compton, page 15].
Each study sought to cure it’s misclassification bias with
the theory outlined in Figure 1: using a physical examin-
ation tuned to specific drugs, officers made amazingly spe-
cific toxicology predictions. An officer’s correct prediction
of cocaine could not have happened unless the subject
really was impaired by the cocaine later found by toxicol-
ogy. Adler wrote:
“Because a specimen may test positive at a time when
the suspect is not under the influence of marijuana, a DRE
evaluation is crucial. Importantly, unless a marijuana posi-
tive from the laboratory is corroborated with evidence of
impairment at the time of the evaluation, it does not speak
to the question of drug influence” [Adler, page 40].
This theory has a number of problems. First, it is circu-
lar. The purpose of a DIE validation study is to discoverwhether LEDAs do in fact accurately identify drug impair-
ment. That proof may not derive from its own conclusion.
Second, the theory conflates side effects with impair-
ment. The mere fact the presence of a drug may be identi-
fied by stereotypic physical side effects need not indicate
the drug is causing mental impairment.
Third, the theory depends on study officers having
made their predictions based on a physical exam. But of-
ficers had access to other facts—circumstances, answers
to questions, searches. It may be officers used these
other facts to identify the presence of a drug in the sub-
ject’s body, and used the presence of a drug to predict
the presence of a drug, the reference standard. One
technique available was to ask, “Have you taken any
drugs?” Adler reported 434 confessions and 682 drug
predictions. If officers predicted a drug each time a
driver confessed, 64% of drug predictions were made
after drivers confessed. When confessions and searches
that found drugs are considered together, as many as
80% of drug predictions were made in cases involving ei-
ther a confession or a positive search. Because certainly
some drivers both confessed and had drugs found, this is
an upper bound.
If DIE validation study officers based their toxicology
predictions on confessions of prescriptions from a doc-
tor, or drug use hours ago, or searches that turned up
drugs or paraphernalia, or physical signs of chronic drug
use like “needle marks, skin rashes, perforation of the
nasal septum” [Compton, page 5], or witness statements,
or a history of drug convictions, then officers based their
correct toxicology predictions on facts independent of
ongoing mental impairment. To the extent this is what
happened, the accuracies reported by Compton and Ad-
ler were subject to misclassification bias and the circular
question DIE validation studies rely on to confirm driver
impairment, “How else could officers have made specific
drug predictions?” has a straightforward answer, “By select-
ing for inclusion in the study people who confessed or had
drugs found in a search”.
Fourth, the theory depends on the false idea that valid-
ation study DRE Opinions were generally correct. They
were not. The LEDA accuracies highlighted by the valid-
ation studies overstate how often DRE officers predicted
drug categories correctly. Compton’s 94% accuracy counts
mistaken—wrong—drug category predictions as correct
so long as toxicology found literally any proscribed drug
other than alcohol. If an officer predicted a CNS stimulant
but toxicology found a CNS depressant, that wrong pre-
diction would contribute a correct score to Compton’s
94% accuracy. Here the DIE validation studies’ misclassifi-
cation bias theory asks us to believe that because the DRE
officer found what he thought were signs of a stimulant
that was not present, the driver must have been impaired
by a depressant whose physical signs were not found.
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dictions, and Compton’s highlighted 94% accuracy was
subject to misclassification bias.
Similarly, Adler’s highlighted 83.5% “supported by la-
boratory analysis” statistic removed wrong predictions
from the accuracy calculation [Adler, page 33]. In fact
officers correctly predicted toxicology findings in only
43% of subjects [Adler, page 34]. Adler’s highlighted ac-
curacy was subject to misclassification bias.
Fifth and finally, the DIE validation studies’ misclassifi-
cation bias theory depends on the premise that valid-
ation studies’ positive toxicology results reflected drugs
present at impairing levels. Some did not. Bigelow and
Adler acknowledged the problem but their methodologies
did not allow it to be quantified. Compton reported that
“In approximately one quarter of the cases that marijuana
was detected, the blood level was reported as <1.0 ng/ml
(an extremely small amount)” [Compton, page 14]. Here
DIE validation studies’ misclassification bias theory is cor-
rect only if marijuana present at these levels was impair-
ing. More likely drivers were not impaired by drugs
present at extremely low levels and Compton’s reported
accuracy was inflated by misclassification bias.QUADAS Item 3—misclassification bias, alcohol
Neither Compton nor Adler excluded subjects whose
breath alcohol concentration (BrAC) tests proved they
had alcohol on board. Both studies’ accuracy calculations
included drivers with alcohol levels above the current
per se legal limits of 0.05 and 0.08% mg/dl. In Compton
53% of drivers in the sample group had alcohol in their
system, with an average BrAC of 0.06% mg/dl, and a
maximum of 0.18% mg/dl [Compton, page 14]. In Adler
19% had BrACs greater than 0.05% mg/dl, with a max-
imum greater than 0.20% mg/dl [Adler, page 54]. In both
Compton and Adler, some subjects classified as impaired
by drugs other than alcohol were certainly impaired by
alcohol. The classification of drivers impaired by alcohol
as impaired by drugs will have caused Compton and
Adler’s reported accuracies to be distorted by misclassifi-
cation bias.QUADAS Item 3—misclassification bias, drug conflation
Bigelow, Compton and Adler each highlighted the accur-
acy with which DRE Opinions predicted “drugs”, as if
“drug” were a homogenous medical entity. This method-
ology fails to classify LEDA results correctly.
First, “drug” is not a homogenous medical entity and
the accuracy of DRE Opinions varies from drug to drug.
Using Compton’s sample group as an example, sensitiv-
ity for PCP (phencyclidine) was 91%, but for cocaine
19% [Compton, page 46]. Counting a correct PCP pre-
diction as indicating the accuracy of cocaine predictionsmisclassifies that PCP result and misstates the accuracy
of the LEDA when an officer predicts cocaine.
Second, because “drug” is not a homogenous medical
entity, bias also arises in the attribution of research ac-
curacies to drugs and drug categories that were not stud-
ied at all. Many of the drugs now claimed for the DIE
were not investigated at all by Bigelow, Compton or Adler
[Table 2]. Counting correct PCP predictions (which were
studied) as indicating the accuracy of dextromethorphan
predictions (which were not) misclassifies study results
and misstates the accuracy of the LEDA when an officer
predicts dextromethorphan.
QUADAS Item 4—disease progression bias
Medical research may involve subjects whose reference
test was performed months after the index test, during
which time the medical condition progressed and be-
came easier to identify, leading to a systematic error
called disease progression bias.
In DIE validation studies a delay between the LEDA
SA and blood or urine sampling may allow the body’s
metabolism to lower drug levels below the reference test
cutoff level, leading to a similar bias. Bigelow did not do
chemical tests. Compton’s index and reference testing
were contemporaneous. Adler considered all detectable
drugs to represent impairment, regardless of how low
the drug level was. Drug levels that in the less than two
hour interval between arrest and sample collection fell
from above to below the laboratory detection level must
have been present at low levels at the time of arrest and
would therefore be correctly classified as non-impairing
in either case. None of the three studies are subject to
disease progression bias.
QUADAS Item 5—verification bias
When the decision whether or not to administer the ref-
erence test depends on the outcome of the index test a
systematic error arises called verification bias. This error
distorts the arithmetic of accuracy calculations in a way
that falsely increases the apparent sensitivity and de-
creases the apparent specificity a study discovers [51].
The errors may be substantial.
Compton and Adler administered the reference test (toxi-
cology) only to people who failed the index test (LEDA).
The sensitivities and specificities discovered by these studies
are subject to verification bias (but see §Accuracies below).
QUADAS Item 6—differential verification bias
When more than one reference test is used and one is
more accurate than the other, and when the decision
about which reference test will be administered depends
on the outcome of the index test, a systematic error
arises called differential verification bias.
Table 2 DIE drug category lists
NHTSA’s DRE student manual Bigelow Compton Adler




2 CNS Stimulants 3 Hallucinogen
2 Diazepam & Secobarbital =
CNS Depressant
4 Cannabis
3 Hallucinogens 2 Barbiturates 5 Inhalants
3 Cocaine 5 Depressants
4 Dissociative Anesthetics 3 Marijuana 4 Cannabis 6 Narcotics
7 Other
5 Opiates 1 PCP
5 Narcotic Analgesics [4 Narcotics (no subjects with
narcotics were tested)]
6 PCP 2 Morphine
6 Inhalants 7 Benzodiazepines 3 Cocaine
8 Alcohol 4 Marijuana
7 Cannabis 5 Barbiturate
6 Benzodiazepine
7 Methamphetamine/Amphetamine
As reflected by NHTSA’s DRE Student Manual, the list of DIE drug categories used in US law enforcement DIE practice differs from the lists validated by Bigelow,
Compton and Adler, whose lists differ from each other. Adler used two different lists. CNS = Central Nervous System. DRE Student Manual, page 2–3; Bigelow,
page 9; Compton, page 7; Adler pages 26, 47.
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tered blood tests for methaqualone and mescaline (refer-
ence) only when officers predicted those drugs (index).
Adler administered a variety of drug-specific toxicology
tests (reference) only when officers predicted those spe-
cific drugs (index). The accuracies reported by Compton
and Alder are subject to differential verification bias.
QUADAS Item 7—incorporation bias
When the index test result necessarily contributes to—is
incorporated into—the interpretation of reference test, a
systematic error arises called incorporation bias. Con-
sider a study investigating whether a hand x-ray can pre-
dict whether a finger fracture will require surgery. The
study’s index test would be the hand x-ray. The refer-
ence test would be whether the patient had surgery. But
in deciding whether to do surgery, the orthopedists
would consider MRI scans, clinical history, physical
exam—and the hand x-rays. Thus the results of the
index test would contribute to the results of the refer-
ence test. This sort of incorporation leads to a bias that
causes studies to discover higher apparent accuracies.
Bigelow, Compton and Adler are subject to incorporation
bias in their diagnosis of impairment. As illustrated in
Figure 1, LEDAs rely on the SFST to diagnose impairment.
Neither Bigelow, Compton or Adler provide or consider a
false positive rate for the SFST’s diagnosis of impairment.
In all three studies, the SFST serves as both index test and
reference test for impairment. The accuracies reported by
these studies are subject to incorporation bias.QUADAS Item 8—index test reproducibility
The accuracy of a diagnostic test depends on which
measurements are made and how they are interpreted.
Tests that make different measurements or use different
interpretations will have different accuracies. The accur-
acies reported by Bigelow, Compton and Adler describe
the accuracy of current law enforcement DIEs only to
the extent current LEDA methods reproduce the LEDAs
investigated in those three studies. QUADAS Item 8
asks, “Do the studies describe their LEDAs in a way that
allows their index testing—and accuracies—to be repro-
duced?” The answer is, “No”. Bigelow, Compton and Ad-
ler did not describe the LEDAs they investigated in
enough detail for that testing to be reproduced.
The LEDA SA includes the gathering of circumstantial
facts, suspect questioning, and a search of the suspect.
These elements of the LEDA are not standardized. None
of the three studies identified which circumstantial facts
officers recorded, what questions they asked, or what
they searched. These elements of the validation studies’
LEDA SAs cannot be reproduced.
The LEDA SA includes a physical exam looking for
“indicators” of impairment or drugs. The three studies
did name some physical maneuvers officers did, with
some maneuvers (e.g. pulse and blood pressure) being
reproducible, and others (e.g. “eyes glassy”, “attitude”,
“condition of the tongue”) being identifiable but not re-
producible. None of the studies reported a standardized
list of physical exam indicators. The studies’ LEDA SA
physical exams are not reproducible.
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of the LEDA SA findings. None of the three studies de-
scribed what their LEDA SA findings were, or how those
findings were combined to formulate DRE Opinions.
The validation studies’ LEDA DRE Opinions cannot be
reproduced.
Current US law enforcement DIE methods do not re-
produce the LEDA methods investigated in Bigelow,
Compton and Adler. The accuracies reported in these
studies do not reflect the accuracy of current DIEs.
QUADAS Item 9—reference test reproducibility
The accuracy with which the results of an index test pre-
dict the results of a reference test may be affected by
variations in how the reference test is performed. Bige-
low’s reference “test”, the record of whether the subject
was given a drug, is reproducible. Compton and Adler do
not describe their reference tests in reproducible detail.
QUADAS Items 10 and 11—review bias
When diagnostic tests whose interpretation is subjective
are investigated in studies that are not blinded, know-
ledge of one test result (reference or index) may influ-
ence the interpretation of the other test in a way that
tends to make the results agree. When this happens a
systematic error arises called review bias. When the ref-
erence test result is known at the time the index test is
interpreted, the error is test review bias. When the index
result is known at the time the reference is interpreted,
the error is diagnostic review bias.
Bigelow’s blinding was partial. When the LEDA-like
SA (index) was interpreted, officers had been told subjects
would have drugs on board and what categories those
drugs would be (reference). Officers were more likely to
correctly choose the index DRE Opinion “CNS stimulant”
because they knew “LSD” and “PCP” and “paint thinner”
and “dextromethorphan” and “hypoglycemia” and “not
naturally coordinated” and “alcohol” were not correct. The
LEDA accuracies Bigelow reported were subject to test
review bias.
Compton and Adler’s officers interpreted LEDA SAs
(index) before toxicology results (reference) were avail-
able. DRE Opinions were not subject to review bias.
The studies themselves were different. Both studies re-
ported what golfers would call Mulligan accuracies, sta-
tistics that counted LEDA DRE Opinions (index) when
toxicology results (reference) showed the opinions were
correct, but didn’t count DRE Opinions when toxicology
showed they were wrong. For example Adler reported
subjects for whom the DRE Opinion correctly predicted
one drug (one true positive prediction), wrongly predicted
a second (one false positive prediction) and wrongly
missed a third (one false negative prediction) [Adler, page
34]. That’s one correct and two wrong index results. ButAdler’s “decisions supported by laboratory analysis” accur-
acy calculation tallied this encounter not as one correct
and two wrong predictions, but as one correct prediction.
The two wrong DRE Opinions disappeared from the cal-
culation. Compton calculated similarly.
Compton’s report that DRE Opinions “identified one
or more drugs correctly in 87% of the suspects” [Comp-
ton, page 16], and Alder’s “DRE decisions were sup-
ported by laboratory analysis for 404 (83.5%) of the 484
specimens” [Adler, page 33], both relied on this method-
ology. Both accuracies reflect review bias. Neither num-
ber correctly quantifies the probability relevant to the
US law enforcement use of DIEs, the probability that an
individual LEDA DRE Opinion is correct.
QUADAS Item 12—clinical review bias
In studies of diagnostic tests whose interpretation is sub-
jective, knowledge of patient characteristics like age, gender,
symptoms or medical history may influence the accuracy of
test interpretations. When this happens a systematic error
arises called clinical review bias.
Because clinical facts (circumstances, questioning,
searches) are defined as part of the LEDA, the accuracies
reported by Bigelow, Compton and Adler cannot, by def-
inition, be subject to this bias.
QUADAS Items 13 and 14—uninterpretable/ intermediate
test results and study withdrawals
Generally some index test results will be uninterpretable.
When uninterpretability is related to disease status, accur-
acy may be biased. Similarly, subjects may be withdrawn
from studies for nonrandom, biasing reasons. Neither
Bigelow, Compton and Adler report uninterpretable or
intermediate test results or study withdrawals. Whether
bias arises due to these factors is unclear.
Accuracies
Diagnostic accuracy research is helpful when it quanti-
fies test performance with externally valid statistics that
allow later users to calculate the predictive values of the
tests they administer. Bigelow, Compton and Adler re-
ported a number of accuracy statistics, from which Bige-
low and Compton highlighted some form of LEDA DRE
Opinion accuracy equivalent to positive predictive value.
Adler highlighted a “decisions supported by toxicology”
accuracy, equivalent to overall accuracy. Adler’s statistic
does not quantify the probability relevant to drugged
driving prosecutions, the probability that a DRE Opin-
ion, of “Yes, drug present” opinion was correct.
Both overall accuracy and PPV are prevalence dependent.
Neither is externally valid. The LEDA accuracies reported
by Bigelow, Compton and Adler are not valid for—do not
quantify the accuracy of—LEDAs now administered by US
law enforcement.
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tion bias with prevalence dependent statistics may overstate
the diagnostic power research discovers. Compton reported
that “When the DREs claimed drugs other than alcohol
were present they were almost always detected in the blood
(94% of the time)” [Compton, page 22]. A simple reading
would suggest this high accuracy was a product of the
LEDA testing study officers did. It was not. The 94% statis-
tic was an artifact of research methodology. Compton’s
173-subject sample consisted not of drivers on the road but
of drivers already arrested for driving impaired by what
non-DRE officers recognized to be drugs. This method
skewed the study sample towards drug impairment; 94%
had drugs on board. Once the sample group was selected,
Compton’s DRE officers performed LEDA SA physical
exams, after which they opined that every driver they tested
had drug(s) present. These opinions were correct 94% of
the time—because 94% of the sample group had drugs
present. This methodology reveals not the diagnostic accur-
acy of the LEDA, but the prevalence of drugs in the sample
population. On this sample had officers abandoned the
LEDA and predicted “impairment” at random, for example
by flipping a coin, they would have achieved the same 94%
accuracy.a Compton’s methodology failed to demonstrate
that the LEDA-like tests the study investigated were any
more accurate than random guessing.
The externally valid statistics commonly used to quan-
tify the ability of a test to tell the difference between
people who do and do not have the target condition are
the paired statistics sensitivity and specificity. The ques-
tion arises, “Can DIE sensitivity and specificity be ex-
tracted from Bigelow, Compton and Adler?”
Bigelow does allow calculation of the sensitivity of its
non-reproducible LEDA-like testing for specific drug-dose
combinations administered in the lab to healthy young
men prescreened to pass the SFST. Because people who
failed a screening SFST were excluded from enrollment in
the study, Bigelow’s false positive count cannot be used to
calculate specificity. (Bigelow’s section “Specificity” actu-
ally described PPV).
Compton and Adler cannot be used to calculate the
sensitivity and specificity of the LEDA-like tests they
studied, for two reasons.
First, the notion that there is one diagnostic accuracy
describing how LEDA DRE Opinions identify drugs pre-
sumes “drug” is a homogenous medical entity. It is not.
Different drugs affect people differently. The accuracy of
DRE Opinions differs from drug to drug. Sensitivity for
PCP is high. Sensitivity for benzodiazepines is low.
There is no externally valid sensitivity for PCP-and-ben-
zodiazepines. That number would vary as the prevalence
of each drug varied and whatever the number was it
would not correctly describe LEDA sensitivity for either
PCP or benzodiazepine.Second, considering each drug individually, Compton
and Adler obtained chemical drug tests only when the
driver failed the DIE. When the DRE Opinion (index)
was “not impaired by a drug”—negative—blood and urine
testing (reference) was not done (Adler included 26 excep-
tions to this rule). Because true negative and false negative
results were excludedb, Compton and Adler’s study de-
signs prevented them from collecting the information
needed to calculate sensitivity and specificity.
Neither Bigelow, Compton nor Adler reported the ex-
ternally valid statistics needed to calculate the diagnostic
accuracy of the LEDA-like testing they investigated or of
the DIEs now used by US law enforcement.
Conclusion
Bigelow, Compton and Adler, the three validation stud-
ies commonly cited in American criminal prosecutions
to quantify the accuracy of current US law enforcement
DIE practice, did no reference testing of driving per-
formance or physical or mental impairment, investigated
tests different from those currently employed by US law
enforcement, used methodologies that biased accuracies,
and reported DIE accuracy statistics that are not exter-
nally valid. The LEDA accuracies reported by these stud-
ies do not quantify the accuracy of the DIE process now
used by US law enforcement. These validation studies
do not validate current DIE practice.
Methods
Defining question
This paper’s defining question has two parts. The first
seeks to clarify current policy and practice: What scien-
tific research is adduced by US law enforcement, and
identified in criminal prosecutions, as evidence of the
diagnostic accuracy of the police DIE process? The sec-
ond part investigates whether the studies identified in
part one do in fact validate current DIE practice: Do the
methodologies used by these studies allow them to cor-
rectly quantify the diagnostic accuracy of Drug Influence
Evaluations as currently administered by US law en-
forcement Drug Recognition Experts?
Identifying sources
Publications of the DIE program-standardizing organiza-
tion, the IACP, were reviewed, including Standards, the
Drug Evaluation and Classification Program web site
DECP.org, and the IACP-approved US law enforcement
DRE Student Manual, which is widely used in American
courts as a foundation for DIE testimony.
Personnel at the IACP were contacted. The Executive
Director was contacted. An IACP committee, the Technical
Advisory Panel (TAP), “provides the IACP Technical infor-
mation and advice as requested concerning the DEC Pro-
gram” [http://www.decp.org/oversight; retrieved March 4,
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pert were contacted. They kindly agreed to help. They were
asked to identify what elements of current US law enforce-
ment DIE testing are standardized, and what scientific re-
search underlies those standards.
An official at the National College of DUI Defense
(NCDD) was contacted. The NCDD is an organization
of American criminal defense attorneys specializing in
alcohol and drug impaired driving law. The NCDD is
the only organization accredited by the American Bar
Association to certify attorneys in the DUI Defense Law
specialty practice area. A founding member and former
Dean of the College, who is an attorney specializing in
DUI law, a law professor and the author of a respected
textbook of DUI law, was contacted and asked to iden-
tify the studies relevant to this paper’s defining question.
Data extraction and evaluation
Studies were selected and their full reports were analyzed.
Data were extracted and analyzed by a single reviewer. Ex-
tracted data included research methodologies pertinent to
the 14 questions posed by the QUADAS tool. The analysis
was done by matching the extracted methodologies with
QUADAS items, seeking to identify whether the studies’
methodologies were likely to bias their reported accuracies.
When a biasing methodology was identified, its likely ef-
fects on each study’s measurement of DIE diagnostic per-
formance were considered. QUADAS presumes research
quantifies diagnostic accuracy with statistics that are exter-
nally valid. The selected studies quantified DIE perform-
ance with accuracy statistics that are internally but not
externally valid; the analysis considered the effects of this
choice of statistics.
Endnotes
aOf the 173 subjects considered in Compton’s accur-
acy calculation, a coin toss would on average predict
drugs in 86.5. Of the 162 subjects with drugs on board,
a coin toss would on average predict drugs in 81. Thus
on average 81/86.5 = 94% of the coin’s “Yes, drugs”
predictions would be correct.
bCompton and Adler did report what appear to be
false negative counts. These exclude true false negatives
(people falsely judged not drug impaired) and tally in-
stead people with one drug on board who were wrongly
judged to be impaired by some other drug. The faux
sensitivities that may be calculated with these numbers
represent only upper bounds of the actual sensitivities,
the true numbers being unknown but certainly smaller.
True negatives and specificity are similarly affected.
Appendix 1
Validation studies’ research methodologies.Bigelow 1985
WHAT: Lab study.
NULL HYPOTHESIS: none. Self identified objective:
“to provide information concerning the validity of sub-
ject examination procedures for identifying and differen-
tiating types of drug intoxication” [Bigelow, page 1].
SUBJECT SELECTION: Young male volunteers were
identified by newspaper advertisements, screened for
good health, trained to do the SFST and excluded if they
could not pass an SFST.
INDEX TEST: DRE officers did a physical exam and
asked unstandardized questions. This procedure was ex-
plicitly different from the procedure used in the field.
Officers formed a LEDA DRE Opinion as to whether the
subject was impaired by a drug, and if so which category
of drug. Available conclusions were limited to CNS stimu-
lant, CNS depressant, marijuana, narcotic, or placebo. No
subjects were given narcotics.
REFERENCE TEST: No reference testing was done.
The reference “test” was the record of which dose of
drug the person had been given. People given any dose
of any drug were counted as impaired. People not given
a drug were counted as not impaired.
ACCURACY REPORTED: Tables tallied officers’ pre-




NULL HYPOTHESIS: none. Self identified objective:
“To validate the LAPD [Los Angeles Police Department]
drug recognition program”, by doing “a field study in
which police officers employed the drug recognition
procedure with real suspects under field conditions”
[Compton, Abstract].
SUBJECT SELECTION: Drivers were stopped and
assessed by non-DRE officers. Drivers judged not to be
impaired were excluded. Drivers judged to be chemically
impaired were arrested and breath alcohol levels were
tested. Arrested drivers whom the non-DRE officers sus-
pected of drug impairment were taken to the police sta-
tion where they underwent a “[c]ursory examination to
determine evidence of drug impairment” [Compton, page
34]. If drug impairment was not apparent on cursory
exam, the driver was excluded. If drug impairment was
apparent on cursory exam, a blood test for drugs was or-
dered. Drivers who refused drug testing were excluded.
Remaining drivers underwent a LEDA SA examination,
after which the DRE officer formed his LEDA Opinion as
to whether the driver was drug impaired, and if so by
which category of drug. Drivers who were judged not im-
paired were excluded. Subjects with alcohol levels above
the legal limit were not excluded. Fifty-two percent of
drivers in the final sample group had alcohol in their
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page 14].
INDEX TEST: DRE officers’ LEDA Opinions.
REFERENCE TEST: Blood test for drugs. Any drug at
any detectable level was interpreted as proving impair-
ment. The principal metabolites of cocaine and marijuana
were excluded; how other metabolites were tested and
interpreted was not reproducibly described.
ACCURACY REPORTED: The final report highlighted
the frequency with which officers’ predictions of a par-
ticular drug were associated with toxicology revealing
any drug at any level: 94%. Contingency tables for some
individual drugs were included (but see §Accuracies).
Adler 1994
WHAT: Field study. Retrospective analysis of Phoenix,
Arizona DRE records. Study results were reported at
least four times [Adler, page 56]; this paper reviews the
final report.
NULL HYPOTHESIS: none. Self identified objective:
to discover whether “DRE methods accomplish their
stated purpose, i.e., the correct identification of drug im-
pairment, as demonstrated by DRE opinions and speci-
men analyses?” [Adler, page ix].
SUBJECT SELECTION: Drivers identified in Phoenix
Police Department records as having been assessed by
DRE officers, arrested for drugged driving, and having
submitted to urine or blood testing between January
1989 and May 1994. Drivers judged not to be drug im-
paired were excluded (for unexplained reasons, twenty-
six drivers judged not to be drug impaired were in-
cluded). Subjects with alcohol in their system were not
excluded; 19% had alcohol levels above the current per
se legal limit of 0.05% mg/dl [Adler, page 54].
INDEX TEST: DRE officers’ LEDA Opinions.
REFERENCE TEST: Urine toxicology. Blood toxicology
used occasionally, details not reproducibly described. Tox-
icology protocol was not reproducibly described. Testing
of drug metabolites was not reproducibly described.
ACCURACY REPORTED: The paper highlighted the
overall accuracy with which officers’ toxicology predic-
tions matched at least one drug found by toxicology:




The LEDA-like process investigated is not reproducible,
was explicitly different from the LEDAs done at the time
and identifiably different from LEDAs now relied on by
US law enforcement. Reported accuracies were subject
to selection bias, spectrum bias, misclassification bias, in-
corporation bias, and review bias. Highlighted accuracystatistics are not externally valid. Limited drug and dose
specific sensitivities can be calculated, specificity and like-
lihood ratio cannot. Did demonstrate that LEDA-like
physical exams have a low sensitivity.
Compton
The LEDA-like process investigated is not reproducible.
Reported accuracies were subject to selection bias, forensic
selection bias, spectrum bias, misclassification bias, verifi-
cation bias, differential verification bias, incorporation bias,
and review bias. Highlighted accuracies statistics are not
externally valid. LEDA sensitivity, specificity, and likeli-
hood ratio cannot be calculated. Highlighted 94% “accur-
acy”, a methodological artifact of combining selection bias
with PPV, fails to demonstrate that diagnostic accuracy is
greater than a coin toss.
Adler
The LEDA-like process investigated is not reproducible.
Reported accuracies were subject to selection bias, fo-
rensic selection bias, spectrum bias, misclassification
bias, verification bias, differential verification bias, in-
corporation bias, and review bias. Highlighted accuracies
are not externally valid. LEDA sensitivity, specificity, and
likelihood ratio cannot be calculated. Highlighted 83.5%
“decisions supported by laboratory analysis” accuracy,
calculated by discarding mistaken DRE Opinions, does
not quantify either the overall accuracy or the PPV of in-
dividual DRE Opinions.
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